VERU INC. Cost of Revenue
VERU INC. (VERU) reported Cost of Revenue of $11.03 million for the 12-month period ending 2024-09-30, per its 10-K filed 2024-12-16.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2024-12-16
- VERU INC. cost of goods and services sold for the quarter ending 2024-09-30 was $3.97M, a 71.03% increase year-over-year.
- VERU INC. cost of goods and services sold for the quarter ending 2024-06-30 was $2.62M, a 23.94% increase year-over-year.
- VERU INC. cost of goods and services sold for the quarter ending 2024-03-31 was $3.46M, a 38.62% increase year-over-year.
- VERU INC. cost of goods and services sold for the quarter ending 2023-12-31 was $990.27K, a 45.16% decline year-over-year.
- VERU INC. cost of goods and services sold for fiscal 2024 was $11.03M, a 26.36% increase from fiscal 2023.
- VERU INC. cost of goods and services sold for fiscal 2023 was $8.73M, a 0.36% decline from fiscal 2022.
- VERU INC. cost of goods and services sold for fiscal 2022 was $8.76M, a 34.27% decline from fiscal 2021.
- VERU INC. cost of goods and services sold for fiscal 2021 was $13.33M, a 12.94% increase from fiscal 2020.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|
| 2024-09-30 | $3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $6.59M derived: sum of 2 quarters · filed 2024-12-16 | $10.04M derived: sum of 3 quarters · filed 2024-12-16 | $11.03M 10-K · filed 2024-12-16 | |
| 2024-06-30 | $2.62M 10-Q · filed 2024-08-08 | $6.07M derived: sum of 2 quarters · filed 2024-08-08 | $7.06M 10-Q · filed 2024-08-08 | $9.38M derived: sum of 4 quarters · filed 2024-12-16 | |
| 2024-03-31 | $3.46M 10-Q · filed 2024-05-08 | $4.45M 10-Q · filed 2024-05-08 | $6.77M derived: sum of 3 quarters · filed 2024-12-16 | $8.88M derived: sum of 4 quarters · filed 2024-12-16 | |
| 2023-12-31 | $990.27K 10-Q · filed 2024-04-01 | $3.31M derived: sum of 2 quarters · filed 2024-12-16 | $5.42M derived: sum of 3 quarters · filed 2024-12-16 | $7.92M derived: sum of 4 quarters · filed 2024-12-16 | |
| 2023-09-30 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $4.43M derived: sum of 2 quarters · filed 2024-12-16 | $6.93M derived: sum of 3 quarters · filed 2024-12-16 | $8.73M 10-K · filed 2024-12-16 | |
| 2023-06-30 | $2.11M 10-Q · filed 2024-08-08 | $4.60M derived: sum of 2 quarters · filed 2024-08-08 | $6.41M 10-Q · filed 2024-08-08 | $8.49M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $2.49M 10-Q · filed 2024-05-08 | $4.30M 10-Q · filed 2024-05-08 | $6.38M derived: sum of 3 quarters · filed 2024-05-08 | $8.92M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $1.81M 10-Q · filed 2024-04-01 | $3.89M derived: sum of 2 quarters · filed 2024-04-01 | $6.42M derived: sum of 3 quarters · filed 2024-04-01 | $8.28M derived: sum of 4 quarters · filed 2024-04-01 | |
| 2022-09-30 | $2.08M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $4.62M derived: sum of 2 quarters · filed 2024-04-01 | $6.47M derived: sum of 3 quarters · filed 2024-04-01 | $8.76M 10-K/A · filed 2024-04-01 | |
| 2022-06-30 | $2.53M 10-Q/A · filed 2023-11-15 | $4.39M derived: sum of 2 quarters · filed 2023-11-15 | $6.68M 10-Q/A · filed 2023-11-15 | $10.02M derived: sum of 4 quarters · filed 2023-11-15 | |
| 2022-03-31 | $1.85M 10-Q · filed 2023-05-11 | $4.15M 10-Q · filed 2023-05-11 | $7.48M derived: sum of 3 quarters · filed 2023-05-11 | $11.27M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $2.29M 10-Q · filed 2023-02-09 | $5.63M derived: sum of 2 quarters · filed 2023-02-09 | $9.41M derived: sum of 3 quarters · filed 2023-02-09 | $11.84M derived: sum of 4 quarters · filed 2023-02-09 | |
| 2021-09-30 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $7.12M derived: sum of 2 quarters · filed 2022-12-05 | $9.55M derived: sum of 3 quarters · filed 2022-12-05 | $13.33M 10-K · filed 2022-12-05 | |
| 2021-06-30 | $3.78M 10-Q · filed 2022-08-11 | $6.21M derived: sum of 2 quarters · filed 2022-08-11 | $10.00M 10-Q · filed 2022-08-11 | $12.18M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $2.43M 10-Q · filed 2022-05-12 | $6.21M 10-Q · filed 2022-05-12 | $8.40M derived: sum of 3 quarters · filed 2022-05-12 | $12.20M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $3.78M 10-Q · filed 2022-02-09 | $5.97M derived: sum of 2 quarters · filed 2022-02-09 | $9.77M derived: sum of 3 quarters · filed 2022-02-09 | $12.28M derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-09-30 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $5.99M derived: sum of 2 quarters · filed 2021-12-02 | $8.50M derived: sum of 3 quarters · filed 2021-12-02 | $11.81M 10-K · filed 2021-12-02 | |
| 2020-06-30 | $3.80M 10-Q · filed 2021-08-12 | $6.31M derived: sum of 2 quarters · filed 2021-08-12 | $9.62M 10-Q · filed 2021-08-12 | $12.51M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $2.51M 10-Q · filed 2021-05-12 | $5.82M 10-Q · filed 2021-05-12 | $8.71M derived: sum of 3 quarters · filed 2021-05-12 | $11.87M derived: sum of 4 quarters · filed 2021-05-12 | |
| 2019-12-31 | $3.31M 10-Q · filed 2021-02-10 | $6.20M derived: sum of 2 quarters · filed 2021-02-10 | $9.36M derived: sum of 3 quarters · filed 2021-02-10 | $11.73M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-09-30 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $6.05M derived: sum of 2 quarters · filed 2020-12-10 | $8.42M derived: sum of 3 quarters · filed 2020-12-10 | $10.15M 10-K · filed 2020-12-10 | |
| 2019-06-30 | $3.16M 10-Q · filed 2020-08-13 | $5.52M derived: sum of 2 quarters · filed 2020-08-13 | $7.25M 10-Q · filed 2020-08-13 | $9.27M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | $2.37M 10-Q · filed 2020-05-13 | $4.09M 10-Q · filed 2020-05-13 | $6.11M derived: sum of 3 quarters · filed 2020-05-13 | $8.54M derived: sum of 4 quarters · filed 2020-05-13 | |
| 2018-12-31 | $1.73M 10-Q · filed 2020-02-12 | $3.74M derived: sum of 2 quarters · filed 2020-02-12 | $6.17M derived: sum of 3 quarters · filed 2020-02-12 | $7.55M derived: sum of 4 quarters · filed 2020-02-12 | |
| 2018-09-30 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-12 | $4.44M derived: sum of 2 quarters · filed 2019-12-12 | $5.82M derived: sum of 3 quarters · filed 2019-12-12 | $7.09M 10-K · filed 2019-12-12 | $7.08M 10-K · filed 2018-12-13 |
| 2018-06-30 | $2.43M 10-Q · filed 2019-08-08 | $3.80M derived: sum of 2 quarters · filed 2019-08-08 | $5.08M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $1.37M 10-Q · filed 2019-05-15 | $2.65M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $1.27M 10-Q · filed 2019-02-13 | ||||
| 2017-09-30 | $6.64M 10-K · filed 2018-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |